Investor Presentaiton
Investor presentation
First three months of 2017
Slide 54
The combined GLP-1 segment accounts for around 10%
with rapid value market growth
GLP-1 value
in bDKK
Global GLP-1 market
VictozaⓇ
dulaglutide
GLP-1 value and patient share of the total
diabetes market
GLP-1 value share of total diabetes
GLP-1 patient share of total diabetes
other
exenatide
Share of total
diabetes care
market
Share %
15%
50
10%
12%
40
30
40
CAGR value¹: 36.3%
8%
10%
10%
10%
30
- 6%
20
20
4%
5%
5%
4%
4%
3%
4%
2%
10
2%
1%
0%
0%
Feb
2012
Feb
2017
1 CAGR for 5-year period
Source: IMS Monthly MAT February, 2017 value figures (DKK)
World North Reg Reg Reg Reg Reg
EU AAMEO J&K LATAM China
America
AAMEO: Africa, Asia, Middle-East and Oceania; J&K: Japan & Korea; LATAM: Latin America
Note: Patient share is indicative and based on data for US, UK, Germany and France.
Source: Patient data; IMS PharMetrix claims data, IMS disease analyser, IMS Midas
Value data; IMS MAT February 2017
changing
diabetes
novo nordiskView entire presentation